Vol.53 No.S-3 December 2005
In vitro antibacterial activity of moxifloxacin
Department of Microbiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa, Japan
Abstract
Moxifloxacin (MFLX), a new synthetic antibacterial agent, was assessed for in vitro antibacterial activity in comparison with tosufloxacin (TFLX), levofloxacin (LVFX), ampicillin (ABPC), cefpodoxime (CPDX), clarithromycin (CAM) and vancomycin (VCM). The results obtained are described below:
1. Assessement of MFLX for antibacterial activity against clinical isolates reveal an MIC90 against Staphylococcus aureus (MRSA) and Enterococcus faecium are above 64 &mu,g/mL, but the MIC90 of MFLX against other species was lower, 0.03-2 &mu,g/mL, and MFLX displayed especially potent activity against S. aureus (MSSA), Streptococcus spp., Haemophilus influenzae, and Moraxella catarrhalis, as pathogens that cause respiratory infections.
2. The MICs of MFLX were higher against the two strains of S. aureus with a grlA mutation in addition to a gyrA mutation and the one strain of E. coli with a gyrA mutation, the same as the other drugs. However, MFLX exhibited potent activity against another strain with mutations in the genes encording DNA gyrase and Topo IV. Also, the MICs of CPDX and VCM for VCM-resistant E. faecalis and E. faecium (VRE) were 32->128 &mu,g/mL, and they were highly resistant. The MICs of MFLX against those species were 1-8 &mu,g/mL, the same as those of TFLX and LVFX.
Key word
moxifloxacin, clinical isolate, drug resistance, MIC
Received
September 21, 2005
Accepted
October 18, 2005
Jpn. J. Chemother. 53 (S-3): 16-20, 2005
